On May 28, 2025, the prestigious journal Advanced Science (Impact Factor: 14.3) published a landmark human clinical trial conducted by Professor Li Yong’s research team from Peking University’s Department of Nutrition and Food Hygiene. The study demonstrates that exogenous nucleotide supplementation significantly reduces biological aging by 3.08 years, as measured by DNA methylation age.
Rigorous Clinical Trial Design
The randomized, double-blind, placebo-controlled study – considered the gold standard in clinical research – involved 121 participants aged 60-70. Funded by Zhen-Ao Shuangdi Enterprise, this 19-week intervention utilized nucleotides derived from yeast enzymolysis.
Two Decades of Scientific Exploration
The research program began in 2006 with innovative “four-generation rat” safety studies, which not only confirmed nucleotide safety but revealed a remarkable 270-day lifespan extension in rats – equivalent to approximately 30 human years.
Building on these findings, Professor Li’s team launched comprehensive anti-aging research in 2019, investigating nucleotides’ effects across multiple levels:
- Whole organism studies
- Cellular mechanisms
- Genetic and molecular pathways
- Gut microbiome interactions
Animal models showed particularly promising results, with SAMP8 mice experiencing:
9.21%-12.6% extended median survival. Equivalent to 8.76-12.01 human years
Implications for Global Anti-Aging Research
The study provides robust scientific evidence for nucleotides as:
- Effective epigenetic age reducers
- Improvers of insulin resistance
- Modulators of visceral fat accumulation
With China’s over-60 population exceeding 300 million and the anti-aging industry growing at 22% annually, scientifically validated nucleotides may emerge as a leading precision anti-aging intervention worldwide.
This “Chinese Solution” represents a significant contribution to international longevity research, offering new possibilities for extending healthspan through nutritional biochemistry.
Related topic:
